about
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupNeuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesNatalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryMRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological SocietyPseudotumoral brain lesions: MRI review.Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabJC Virus PCR Detection Is Not Infallible: A Fulminant Case of Progressive Multifocal Leukoencephalopathy with False-Negative Cerebrospinal Fluid Studies despite Progressive Clinical Course and Radiological Findings.7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case studyCurrent and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Concomitant granule cell neuronopathy in patients with natalizumab-associated PMLProgressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod.Lack of increased signal intensity in the dentate nucleus after repeated administration of a macrocyclic contrast agent in multiple sclerosis: An observational study.Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.Natalizumab in relapsing-remitting multiple sclerosis.Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Progressive multifocal leukoencephalopathy and black fungus in a patient with rheumatoid arthritis without severe lymphocytopenia.High b-value diffusion-weighted imaging in progressive multifocal leukoencephalopathy in HIV patients.MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
P2860
Q26780412-E65875D8-DF13-4B57-A738-76F46927F5EEQ26781389-0BEB718F-91C7-4F70-86F0-FA18C0DB9547Q28555138-A79EC5AB-3658-49B8-BB4E-D1DD8DF1E9A6Q30981999-92DCD239-CDD1-4273-A707-901C724FC1FDQ31123447-BD6A591F-52D1-4297-82FE-DB33183113B2Q31144263-C1715569-BE9B-4735-9DF3-8029984D56A0Q34818048-0EEC45C5-05FD-48E1-9167-356B324FDA4AQ35226750-0E24413A-CA81-4769-8B6E-FDD07461C982Q36242324-8022E2D4-B585-4D88-94B4-209C2C493560Q36352813-65BF64F6-9CED-4E46-8BA0-FE7F6E9DDBC3Q36783871-35899ED8-BA2A-4A96-A1A4-6CB3D5BF933BQ37475542-5122EE8B-E997-4AC8-8DE8-1FA61FDD2229Q37605738-1D3DDDEE-8D96-4E0E-B7C2-4623348EBB09Q38591114-34ABF811-00EE-4F7A-9FF0-D1E97B5664CEQ38786252-D9B1C0A2-A176-4892-A2FA-32F0C57FEF05Q39211049-8E1C36E0-3ED0-4093-AE65-E287E761584AQ39325788-E3751254-3A11-42C5-AFD8-8CDDB1DCD552Q39391443-5AEBF884-768D-4C33-80BA-1A5819D389C2Q40061894-256F6AFF-5896-4AA9-9AC6-5E9879D049A1Q40271075-B910DE13-FAD2-4817-BBE9-BE3676FC9AF5Q40342277-A1B8FEBE-0174-41C9-9CF6-8E27D8B17DB9Q40619670-F2949370-9902-4EE2-9B08-35EB9EFAD380Q41126166-98680421-D56B-4F70-850B-D9DB50384143Q41361912-DF6E0D84-DED4-43FA-B82C-B8906A36C791Q51100906-E14A70B5-A320-4EA3-A180-A46D7200B5FFQ52150367-861136C9-A841-48BF-A026-D516982585E3Q52659119-4A549D36-0D13-45D4-AE6D-C0B77516F623
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
MRI pattern in asymptomatic natalizumab-associated PML.
@en
type
label
MRI pattern in asymptomatic natalizumab-associated PML.
@en
prefLabel
MRI pattern in asymptomatic natalizumab-associated PML.
@en
P2093
P2860
P356
P1476
MRI pattern in asymptomatic natalizumab-associated PML.
@en
P2093
Alex E L van Golde
Anke Vennegoor
Bob W van Oosten
Dorine A Siepman
Joep Killestein
Jop Mostert
Marlieke de Vos
Martijn D Steenwijk
Mike P Wattjes
Nancy D Richert
P2860
P304
P356
10.1136/JNNP-2014-308630
P407
P577
2014-09-09T00:00:00Z